# FDA Compliance Evaluation — mounthydra.com
## Model Comparison: DGX (GPT-OSS 120B) vs Claude Sonnet

---

## DGX (GPT-OSS 120B) Evaluation

### HIGH Severity Issues
1. **"Improved clinical performance and outcomes"** — Direct drug efficacy claim without NDA/BLA
2. **"Clinics report faster recovery and better results"** — Unsubstantiated testimonial/clinical outcome claim, triggers both FDA + FTC
3. **"FDA Certified cell line" / DMF language** — DMF ≠ certification. Misleading consumers into thinking FDA approved
4. **"Rejuvenate skin... trigger collagen and elastin production"** — Cosmetic drug claim; if product affects skin structure, it's a drug not a cosmetic
5. **Dual "Cosmetic / RUO" labeling** — Can't sell cosmetic + RUO simultaneously with therapeutic language

### MEDIUM Severity
6. "Promoting regeneration, reducing inflammation, modulating immune system" — Borderline drug claims
7. "Molecules for healing and immune support" — Therapeutic territory
8. "Trusted by 200+ clinics" — Implied endorsement
9. "Clinical-grade, GMP" — Acceptable for manufacturing but misleading when paired with therapeutic claims
10. "Premium", "excellence" superlatives

### LOW Severity
11. Technical specs (97% viability, 100B/ml) — Fine if verifiable
12. Site gating — Good practice but doesn't cure other violations

### Notable: DGX provided a 7-step action plan with specific CFR references (21 CFR 310, 312, 610, 801, 820) and recommended SOPs.

---

## Claude Sonnet Evaluation

### HIGH Severity Issues
1. **Drug claims while marketing as cosmetic/research** — "promoting regeneration, reducing inflammation, modulating immune system", "healing and immune support", "improved clinical performance"
2. **Misleading FDA registration** — "FDA Certified cell line" is false; DMFs don't constitute certification

### MEDIUM Severity
3. "Trigger collagen and elastin production" — Beyond cosmetic scope
4. "Clinics report faster recovery" — Unsubstantiated clinical outcomes
5. "Clinical-grade" terminology — Implies medical use, contradicts cosmetic/research classification

### LOW Severity
6. Professional gating — Doesn't protect against drug classification

### Classification Risk: Products are "illegally marketed drugs" based on intended use evidenced by claims. Recommends 510(k) or IND pathway.

---

## Head-to-Head Comparison

| Dimension | DGX (GPT-OSS 120B) | Claude Sonnet |
|-----------|-------------------|---------------|
| Issues identified | 13 distinct items | 6 categories |
| Granularity | Claim-by-claim with tables | Grouped by theme |
| Regulatory citations | Specific CFRs (21 CFR 310, 610, 801) | General references |
| Remediation detail | 7-step action plan with SOPs | 5 bullet recommendations |
| Depth | Very detailed, ~3,500 words | Concise, ~800 words |
| Accuracy | Solid; minor typo ("MouthHydra") | Clean, no errors |
| Actionability | High — specific rewrites suggested | Medium — directional guidance |
| Speed | ~60 seconds | ~30 seconds |
| Cost | $0 (local) | API cost |

### Verdict
Both models correctly identified the core issues: drug claims masquerading as cosmetic/research, FDA DMF misrepresentation, and unsubstantiated clinical outcomes. 

**DGX was more thorough** — it caught more individual issues, provided specific CFR references, and gave concrete rewrite suggestions. The action plan was more implementable.

**Sonnet was more concise and organized** — cleaner structure, faster to read, hit the key points without the noise.

For a regulatory review like this, DGX's extra detail is genuinely useful. The $0 cost is a significant advantage for bulk analysis work.
